Dopamine mediates cocaine-induced conditioned taste aversions as demonstrated with cross-drug preexposure to GBR 12909.

Pharmacology, Biochemistry, and Behavior
Katherine M SerafineAnthony L Riley

Abstract

Although cocaine readily induces taste aversions, little is known about the mechanisms underlying this effect. It has been suggested that its inhibitory effects at one of the monoamine transporters may be mediating this suppression. Using the cross-drug preexposure preparation, the present series of studies examined a possible role of dopamine (DA) in this effect. Male Sprague-Dawley rats were exposed to cocaine (18 mg/kg; Experiment 1) or the selective DA transporter (DAT) inhibitor GBR 12909 (50 mg/kg; Experiment 2) prior to the pairing of a novel saccharin solution with injections of GBR 12909 (32 mg/kg), cocaine (18 mg/kg) or vehicle in a conditioned taste aversion (CTA) procedure. Preexposure to cocaine attenuated aversions induced by itself but not aversions induced by GBR 12909 (Experiment 1). Conversely, preexposure to GBR 12909 attenuated aversions induced by itself and cocaine (Experiment 2). This asymmetry suggests that cocaine and GBR 12909 induce CTAs via similar, but non-identical, mechanisms. These data are discussed in the context of previous work demonstrating roles for dopamine, norepinephrine and serotonin in cocaine-induced CTAs.

References

Jun 1, 1978·Pharmacology, Biochemistry, and Behavior·A J GoudieE W Thornton
Jul 1, 1992·Pharmacology, Biochemistry, and Behavior·A Van HestB Olivier
Jul 8, 1992·Annals of the New York Academy of Sciences·R A WiseW Trojniar
Feb 1, 1991·Pharmacology, Biochemistry, and Behavior·C M FerrariA L Riley
Jun 1, 1985·Pharmacology, Biochemistry, and Behavior·T HuntZ Amit
Jan 1, 1987·Neuroscience and Biobehavioral Reviews·T Hunt, Z Amit
Oct 1, 1974·Journal of Comparative and Physiological Psychology·A E LeBlanc, H Cappell
Jun 1, 1974·Physiology & Behavior·R F Berman, D S Cannon
Jan 1, 1995·Neuroscience and Biobehavioral Reviews·L A Parker
Jan 15, 1999·Psychopharmacology·J GommansB Olivier
Apr 9, 1999·Nature Neuroscience·B A RochaM G Caron
Apr 26, 2001·Proceedings of the National Academy of Sciences of the United States of America·I SoraG R Uhl
Sep 6, 2002·Pharmacology, Biochemistry, and Behavior·Ivana Grakalic, Anthony L Riley
Mar 17, 2004·Neuroscience and Biobehavioral Reviews·Aaron Ettenberg
Mar 3, 2005·Pharmacology, Biochemistry, and Behavior·Gregory R Simpson, Anthony L Riley
Dec 13, 2005·Pharmacology, Biochemistry, and Behavior·Kevin B FreemanAnthony L Riley
Nov 30, 2007·Pharmacology, Biochemistry, and Behavior·Kevin B FreemanAnthony L Riley
Sep 13, 2008·European Journal of Pharmacology·Hakan KayirTayfun I Uzbay
Nov 26, 2008·Pharmacology, Biochemistry, and Behavior·Katherine M Serafine, Anthony L Riley
Jul 30, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Santiago Perez-LloretUNKNOWN French Association of Regional Pharmacovigilance Centers
Dec 2, 2010·Physiology & Behavior·Anthony L Riley
Jan 4, 2012·Physiology & Behavior·Katherine M SerafineAnthony L Riley

❮ Previous
Next ❯

Citations

Dec 18, 2013·Psychopharmacology·Nabeel RkiehFrancesco Leri
Oct 7, 2014·Pharmacology, Biochemistry, and Behavior·Heather E KingAnthony L Riley
Feb 19, 2013·Pharmacology, Biochemistry, and Behavior·Maria A BriscioneAnthony L Riley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here